Lung cancer is a malignancy that originates in the cells lining the airways and air sacs of the lungs. Like all cancers, it begins when the normal controls that govern cell growth and division break down genetic mutations accumulate in a cell, causing it to replicate uncontrollably and resist the signals that would normally trigger cell death. Over time, these abnormal cells form a tumour. The lungs are particularly significant as a site of cancer for several reasons. They are large, highly vascular organs meaning tumours within them have ready access to the bloodstream and lymphatic system, which facilitates spread to other parts of the body. The lungs also have significant functional reserve; they can accommodate considerable tumour growth before symptoms become obvious enough to prompt medical attention. This combination of easy spread and late symptom onset explains why lung cancer is so often diagnosed at an advanced stage.

Primary lung cancer cancer that originates in the lung is what this guide addresses. Secondary lung cancer, where cancer from another organ spreads to the lung is a different entity that is managed according to the primary cancer's origin. Lung cancer is the most commonly diagnosed cancer and the most common cause of cancer death in both men and women globally. In India, lung cancer ranks among the leading cancer diagnoses, with tobacco use driving the majority of cases and air pollution contributing meaningfully to the burden of disease.

Lung cancer is not a single disease. It is a category of related but biologically distinct malignancies that arise from different cell types within the lung, behave differently, spread differently, and respond differently to treatment. Understanding the type is the essential first step in determining the right treatment approach.

Non Small Cell Lung Cancer (NSCLC)

Non small cell lung cancer accounts for approximately 85 percent of all lung cancers and is itself divided into three main subtypes.

• Adenocarcinoma is the most common subtype, accounting for roughly 40 percent of all lung cancers. It typically arises in the peripheral regions of the lung in the smaller airways and alveolar cells and is the most common type in non smokers, women, and younger patients. Adenocarcinoma is the subtype most likely to harbor targetable genetic mutations particularly EGFR, ALK, ROS1, KRAS, and BRAF mutations which has driven much of the targeted therapy revolution of the past decade.
• Squamous cell carcinoma develops from the flat cells lining the central airways the bronchi and is strongly associated with smoking. It tends to be centrally located, near the main bronchi, and is more likely than adenocarcinoma to cause early symptoms such as cough and haemoptysis (coughing blood). It is less commonly driven by targetable mutations, though immunotherapy has shown significant efficacy.
• Large cell carcinoma is a less common subtype diagnosed by exclusion when cancer cells lack the microscopic features of adenocarcinoma or squamous cell carcinoma. It tends to grow and spread quickly and is often diagnosed at an advanced stage.

Small Cell Lung Cancer (SCLC)

Small cell lung cancer accounts for approximately 15 percent of lung cancers but is biologically and clinically distinct from NSCLC in important ways. It grows very rapidly, spreads early often before it causes symptoms and is almost exclusively associated with heavy tobacco smoking. It is highly sensitive to chemotherapy and radiotherapy initially, but frequently relapses after initial treatment. Surgery plays a very limited role because most patients already have systemic spread at diagnosis.

Carcinoid Tumours

Lung carcinoids are rare neuroendocrine tumours that grow more slowly than typical lung cancers. Typical carcinoids have excellent prognosis with surgery, while atypical carcinoids are more aggressive. They are not strongly associated with smoking.

Staging determining how far the cancer has spread is the single most important determinant of treatment approach and prognosis. Both NSCLC and SCLC are staged, though the systems differ.

NSCLC Staging (TNM System)

• Stage I : the cancer is confined to the lung and has not spread to lymph nodes or distant sites. Stage IA tumours are smaller than 3 cm; stage IB are 3 to 4 cm. Surgery is the primary treatment, with excellent long term outcomes.
• Stage II : the cancer involves the lung and nearby lymph nodes within the chest, or is a larger primary tumour. Surgery combined with adjuvant chemotherapy is the standard approach.
• Stage III : the cancer has spread to lymph nodes in the mediastinum (the central chest) or to nearby structures. Stage IIIA may be surgically resectable; stage IIIB and IIIC are generally treated with concurrent chemotherapy and radiotherapy rather than surgery. This is one of the most complex stages requiring multidisciplinary decision making.
• Stage IV : the cancer has spread to the opposite lung, the fluid around the lungs or heart, or to distant organs most commonly the brain, bones, adrenal glands, and liver. Stage IV is considered metastatic disease. While not curable in most cases, modern treatments particularly targeted therapy and immunotherapy have transformed outcomes, with some patients living years with well controlled disease.

SCLC Staging

SCLC uses a simpler two stage system. 

• Limited stage : disease confined to one side of the chest that can be encompassed in a single radiation field is treated with chemotherapy and concurrent radiotherapy.
• Extensive stage : disease that has spread beyond these boundaries is treated primarily with chemotherapy and immunotherapy.

Lung cancer is notoriously silent in its early stages; the lungs have no pain receptors in their tissue, and tumours can grow considerably before producing any symptoms. This is one of the primary reasons so many cases are diagnosed at an advanced stage.

• Persistent cough is the most common symptom present in approximately 50 to 75 percent of patients at diagnosis. A new cough that does not resolve after three weeks, or a change in the character of a long-standing cough in a smoker, warrants medical evaluation.
• Haemoptysis coughing up blood or blood-stained mucus is one of the most alarming symptoms and should always prompt immediate medical assessment. Even small amounts of blood in the sputum are significant in the context of lung cancer.
• Breathlessness progressive shortness of breath, either at rest or on exertion develops as the tumour obstructs airways, causes fluid to accumulate around the lung (pleural effusion), or reduces overall lung capacity.
• Chest pain a persistent ache or sharp pain in the chest, shoulder, or back that does not change with position can indicate involvement of the chest wall, pleura, or ribs.
• Hoarseness develops when the tumour or enlarged lymph nodes compress the recurrent laryngeal nerve, affecting the vocal cords.
• Unexplained weight loss and loss of appetite losing more than five percent of body weight without trying are general cancer symptoms that, combined with respiratory complaints, heighten suspicion.
• Recurrent chest infections repeated bouts of pneumonia or bronchitis in the same lung region occur when a tumour partially obstructs a bronchus, causing secretions to pool and become infected.
• Symptoms of metastatic spread include persistent headaches or neurological changes (brain metastases), bone pain (bone metastases), and abdominal symptoms (liver or adrenal metastases).
• Superior vena cava (SVC) syndrome facial and arm swelling, headache, and visible distension of neck veins is a specific complication of tumours or lymph nodes compressing the superior vena cava and requires urgent treatment.

The causes of lung cancer are better understood than those of almost any other cancer which is both scientifically significant and clinically important, because most of the major causes are preventable.

• Tobacco smoking is responsible for approximately 85 percent of all lung cancer cases. Every cigarette delivers over 70 known carcinogens directly to the lung epithelium. Tobacco carcinogens particularly polycyclic aromatic hydrocarbons, nitrosamines, and benzene damage DNA in airway cells, causing mutations that accumulate over years and decades. The risk rises proportionally with both the number of cigarettes smoked per day and the number of years of smoking. The lifetime risk of lung cancer in a heavy lifelong smoker is approximately 15 to 20 percent.
• Passive smoking regular inhalation of second-hand cigarette smoke raises lung cancer risk by approximately 20 to 30 percent compared to those with no exposure. It is a significant cause of lung cancer in non-smoking partners of smokers.
• Air pollution including outdoor pollution from vehicle emissions, industrial combustion, and particulate matter is a recognised lung carcinogen classified as Group 1 by the International Agency for Research on Cancer. Urban air quality is a particularly significant factor in Indian cities, contributing to lung cancer incidence in non smokers.
• Radon gas a naturally occurring radioactive gas that seeps from rock and soil into buildings is the leading cause of lung cancer in non smokers in many countries. Radon exposure is estimated to cause approximately 3 to 14 percent of all lung cancers.
• Occupational exposures including asbestos, arsenic, chromium, nickel, beryllium, cadmium, and diesel exhaust are significant causes in workers with sustained occupational exposure.
• Genetic factors including inherited mutations in tumour suppressor genes and variations in carcinogen metabolism genes influence individual susceptibility to lung cancer for a given level of exposure.
• Prior lung disease particularly chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis independently increases lung cancer risk, likely because of chronic inflammation and disrupted cell turnover in damaged lung tissue.

Accurate diagnosis is the foundation of all treatment planning establishing not just that cancer is present, but its type, molecular characteristics, and extent of spread.

• Chest X-ray is often the initial investigation either prompted by symptoms or discovered incidentally. A mass, nodule, or opacity on chest X-ray raises suspicion but cannot confirm cancer. All suspicious X-ray findings require further investigation with CT scanning.
• CT scan of the chest is the primary imaging tool for lung cancer evaluation. It characterises the size, location, and features of the primary tumour, assesses mediastinal lymph nodes, and identifies pleural effusion. A CT scan of the abdomen and pelvis is performed simultaneously to assess for distant metastases. CT with contrast is preferred for comprehensive staging.
• PET-CT scan (positron emission tomography combined with CT) is essential for accurate staging. PET imaging uses a radioactive glucose analogue that is taken up preferentially by metabolically active cancer cells showing both the primary tumour and any sites of spread with high sensitivity. It is the most accurate non invasive staging tool for NSCLC.
• Brain MRI is performed routinely in patients with stage III and IV NSCLC, and in all patients with SCLC, to identify brain metastases which are common, particularly in adenocarcinoma.
• Bronchoscopy passing a flexible camera down the airways under local anaesthesia and sedation allows direct visualisation of central tumours and biopsy of accessible lesions. Endobronchial ultrasound (EBUS) allows simultaneous sampling of mediastinal lymph nodes.
• CT-guided biopsy passing a needle through the chest wall into a peripheral tumour under CT guidance obtains tissue from tumours that cannot be reached by bronchoscopy.
• Thoracoscopy (VATS) video assisted thoracoscopic surgery may be used diagnostically to sample pleural tissue or lymph nodes when other biopsy methods have not yielded a diagnosis.
• Molecular and genetic testing of tumour tissue is now standard of care for all NSCLC patients and is one of the most important advances in lung cancer medicine. Testing for EGFR mutations, ALK rearrangements, ROS1 rearrangements, KRAS G12C mutations, BRAF V600E mutations, MET exon 14 skipping, RET rearrangements, NTRK fusions, and PD-L1 expression guides decisions about targeted therapy and immunotherapy. Liquid biopsy testing circulating tumour DNA from a blood sample is increasingly used alongside tissue biopsy to identify mutations and monitor treatment response.
• Pulmonary function tests assess respiratory reserve in patients being considered for surgical resection ensuring sufficient lung function will remain after the planned surgery.

Lung cancer treatment in Chennai at specialist centres encompasses the full range of modern therapeutic modalities surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy deployed individually or in combination according to each patient's tumour type, stage, molecular profile, and overall health.

Surgery

Surgery offers the best chance of cure in early stage NSCLC and is the primary treatment for stage I and II disease. The standard surgical procedure is lobectomy removal of the lobe of the lung containing the tumour performed via video assisted thoracoscopic surgery (VATS) or robotic assisted surgery at most modern centres. VATS lobectomy achieves equivalent oncological outcomes to open surgery with significantly less pain, shorter hospital stay, and faster recovery.

For patients with borderline lung function, more limited resections segmentectomy or wedge resection preserve more lung tissue while still removing the cancer. Pneumonectomy removal of an entire lung is reserved for centrally located tumours when lesser resections are not anatomically feasible.Minimally invasive thoracic surgery both VATS and robotic is now standard at lung cancer treatment in Chennai specialist centres, with outcomes comparable to international benchmarks.

Radiotherapy

• Stereotactic body radiotherapy (SBRT) also called stereotactic ablative radiotherapy (SABR) delivers precisely targeted, high dose radiation to small lung tumours in three to five sessions. It is the standard treatment for early stage NSCLC in patients who are medically inoperable and achieves local control rates comparable to surgery in selected patients. Modern SBRT systems use real time tumour tracking to account for respiratory movement, ensuring maximum precision.
• Conventional radiotherapy delivered over multiple sessions is used for locally advanced disease, as part of combined chemoradiotherapy for stage III NSCLC, and for palliative treatment of symptoms such as pain, haemoptysis, or SVC syndrome.
• Prophylactic cranial irradiation (PCI) preventive brain radiotherapy is used in selected patients with SCLC to reduce the risk of brain metastases.

Chemotherapy

Platinum based chemotherapy carboplatin or cisplatin combined with a second agent such as pemetrexed, paclitaxel, or docetaxel remains the backbone of treatment for patients without targetable mutations and is used in combination with immunotherapy in first line treatment of advanced NSCLC. It is the primary treatment for SCLC in combination with etoposide. Adjuvant chemotherapy given after surgical resection reduces recurrence risk in stage II and selected stage IB NSCLC.

Targeted Therapy

Targeted therapy represents the most significant advance in lung cancer treatment of the past two decades and access to these medications is an essential feature of quality Treatment Lung Cancer in Chennai.

• EGFR inhibitors osimertinib, erlotinib, gefitinib, afatinib are oral tablets that block the epidermal growth factor receptor, which drives tumour growth in approximately 30 to 50 percent of Asian patients with adenocarcinoma who have EGFR mutations. Osimertinib (Tagrisso) is the current first line standard a once daily tablet that achieves median progression free survival of 18 to 20 months and has shown a meaningful overall survival benefit compared to chemotherapy. EGFR mutations are particularly common in non smokers and in Indian and Asian populations.
• ALK inhibitors alectinib, brigatinib, lorlatinib target the ALK gene rearrangement, present in approximately 3 to 5 percent of NSCLC patients. Alectinib achieves extraordinary response rates and is the current first line standard for ALK positive disease.
• Other targeted agents include selpercatinib (RET), capmatinib (MET), entrectinib and larotrectinib (NTRK), and dabrafenib plus trametinib (BRAF V600E) each targeting a specific oncogenic driver identified through molecular testing.

Immunotherapy

• Immunotherapy specifically PD-1 and PD-L1 checkpoint inhibitors has transformed advanced NSCLC treatment. These drugs release the immune system's brakes, allowing it to recognise and attack cancer cells.
• Pembrolizumab (Keytruda) is approved as first line monotherapy for NSCLC patients with high PD-L1 expression (TPS ≥50%) without EGFR or ALK alterations, and in combination with chemotherapy for patients with lower PD-L1 expression. In high PD-L1 expressors, pembrolizumab monotherapy achieves five year survival rates of approximately 30 percent remarkable for a disease that previously had median survival of under a year at this stage.
• Atezolizumab, nivolumab, and durvalumab are additional checkpoint inhibitors used in various treatment settings in NSCLC and SCLC.

Advanced lung cancer treatment in Chennai at leading centres incorporates cutting edge technology across diagnosis, treatment planning, and delivery.

• Robotic assisted thoracic surgery using the da Vinci or similar surgical robotic systems provides surgeons with enhanced three dimensional visualisation, greater instrument precision, and improved access to difficult anatomical locations. Robotic lobectomy achieves equivalent oncological outcomes to VATS with potentially faster recovery in selected patients.
• Endobronchial ultrasound (EBUS) allows real time ultrasound guidance during bronchoscopy for precise sampling of mediastinal lymph nodes critical for accurate staging and avoiding unnecessary surgery.
• Navigational bronchoscopy using electromagnetic navigation or robotic platforms guides bronchoscopes to peripheral lung lesions that cannot be reached by conventional bronchoscopy, enabling biopsy without chest wall puncture.
• 4D-CT and respiratory gated radiotherapy account for the movement of lung tumours during breathing, ensuring that radiotherapy beams track the tumour precisely through each respiratory cycle.
• Proton beam therapy available at selected specialist centres delivers radiation with a specific physical profile that deposits maximum energy within the tumour while minimising dose to surrounding normal tissue. It is particularly valuable for tumours near critical structures and for re-irradiation scenarios.
• Next generation sequencing (NGS) of tumour tissue enables comprehensive molecular profiling testing for all relevant mutations simultaneously in a single test guiding the selection of targeted therapies and identifying clinical trial eligibility. Leading centres offering Advanced Lung Cancer Treatment in Chennai incorporate NGS as standard of care for all NSCLC patients.
• Liquid biopsy detecting circulating tumour DNA in peripheral blood allows non invasive molecular profiling when tissue biopsy is not feasible, and enables monitoring of treatment response and early detection of resistance mutations.

While lung cancer can affect anyone, certain factors substantially elevate personal risk and should inform decisions about screening and prevention.

• Current or former smoking is the dominant risk factor accounting for approximately 85 percent of cases. The risk is proportional to pack years (number of packs per day multiplied by years of smoking). Former smokers retain elevated risk for decades after cessation it never fully returns to the level of a never smoker, though it decreases progressively with years of abstinence.
• Age most lung cancers are diagnosed in people over 50, with peak incidence in the sixth and seventh decades.
• Family history of lung cancer in a first degree relative particularly in a non smoker raises personal risk and may reflect shared environmental exposures, genetic susceptibility, or both.
• Occupational exposure to asbestos, arsenic, chromium, nickel, diesel exhaust, or ionising radiation represents a significant occupational risk that requires workplace safety measures and health monitoring.
• Chronic lung disease particularly COPD independently increases lung cancer risk, likely through shared mechanisms of chronic inflammation and epithelial disruption.
• Air pollution exposure is increasingly recognised as a significant risk factor, particularly relevant in Indian urban settings where PM2.5 levels frequently exceed safe thresholds.
• Low dose CT screening is now recommended for high risk individuals in many countries specifically current or former heavy smokers aged 50 to 80 and has been shown to reduce lung cancer mortality by detecting cancers at earlier, more treatable stages. This is an increasingly available service at centres offering lung cancer treatment in Chennai.

Prevention of lung cancer focuses primarily on eliminating or reducing exposure to its most significant known causes.

• Stopping smoking is the single most impactful step anyone can take to reduce their lung cancer risk. The benefit begins immediately after cessation and continues to increase over years. After ten years of abstinence, lung cancer risk falls to approximately half that of a continuing smoker. After fifteen years, it approaches though does not reach that of a never smoker. No tool for lung cancer prevention is more powerful than quitting.
• Never starting smoking is even more effective which is why tobacco control measures targeting young people, including advertising bans, plain packaging, and taxation, are among the most important public health interventions for lung cancer prevention.
• Avoiding second hand smoke ensuring a smoke free home and workplace meaningfully reduces passive exposure risk, particularly for children and non smoking partners.
• Reducing air pollution exposure using air purifiers indoors, avoiding peak pollution hours for outdoor exercise, wearing appropriate masks in heavily polluted environments, and supporting broader environmental policies that reduce urban air pollution is particularly relevant in Indian cities.
• Workplace safety proper use of personal protective equipment, adequate ventilation, and strict adherence to occupational safety regulations when working with known carcinogens protects against occupational lung cancer risk.
• Testing homes for radon particularly in areas known for elevated geological radon levels and implementing mitigation measures where levels are high reduces an underappreciated lung cancer risk factor.
• Maintaining a healthy diet rich in vegetables and fruits provides antioxidants that may offer some protective effect against oxidative DNA damage, though dietary interventions are far less impactful than smoking cessation.
• Regular health screening for high risk individuals low dose CT scanning for eligible smokers and former smokers catches lung cancer at an earlier, more treatable stage. Several centres providing lung cancer treatment in Chennai offer organised lung cancer screening programmes.

• The Lung Cancer Treatment Cost in Chennai varies considerably depending on the type and stage of cancer, the treatment modality required, the specific hospital and surgeon, and the technologies involved.
• Surgery lobectomy or segmentectomy costs vary based on whether VATS, robotic, or open approaches are used, the complexity of the case, and the duration of hospital stay. Robotic surgery typically carries a higher procedural cost than VATS but may reduce overall costs through shorter hospitalisation.
• Targeted therapy costs particularly for newer generation agents like osimertinib were historically high, but generic versions of several EGFR and ALK inhibitors are now available in India, significantly reducing the financial burden for many patients. Immunotherapy costs depend on the agent, dosing schedule, and duration of treatment.
• Radiotherapy costs depend on the technology used conventional radiotherapy, IMRT, SBRT, or proton therapy with SBRT and proton therapy typically commanding higher costs than conventional approaches.
• The Lung Cancer Treatment Cost in Chennai at government and trust hospitals is substantially lower than at private centres, and several insurance schemes including Ayushman Bharat and state level schemes cover significant portions of cancer treatment costs. Most private hospitals also have financial counselling services to help patients access insurance, government schemes, and payment plans.

Lung cancer is a serious diagnosis but it is not the uniformly hopeless one it was even a decade ago. The introduction of targeted therapies, the advent of immunotherapy, the refinement of surgical techniques, and improvements in radiotherapy precision have collectively transformed outcomes for patients at every stage. Patients with advanced, metastatic NSCLC who have targetable mutations or high PD-L1 expression are living years longer than patients in the same situation a decade ago and research continues to expand options further. For patients and families in South India, Advanced Lung Cancer Treatment in Chennai is now available at specialist centres that match the standard of care found at leading international institutions with molecular diagnostics, multidisciplinary tumour boards, robotic surgery, SBRT, and access to all approved systemic therapies including targeted agents and immunotherapy.

The most important steps remain consistent: do not smoke, and if you do, stop. Know the warning signs. Seek medical assessment promptly when they appear. If you are in a high risk group, ask your doctor about screening. And if you or someone you love receives a lung cancer diagnosis, seek specialist care without delay at a centre with the expertise, technology, and multidisciplinary approach that this disease demands. Treatment of lung cancer in Chennai at a specialist thoracic oncology centre, with a team that includes thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, and pathologists working together, gives every patient the best possible chance of the best possible outcome.